Get KALA BIO alerts:KALA BIO, Inc. (NASDAQ:KALA – Free Report) – Investment analysts at Lifesci Capital decreased their Q3 2025 earnings per share (EPS) estimates for shares of KALA BIO in a research report issued on Monday, September 29th. Lifesci Capital also issued estimates for KALA BIO’s Q4 2025 earnings at ($1.44) EPS, FY2025 earnings at ($6.44) EPS, Q1 2026 earnings at ($0.30) EPS, Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.32) EPS and FY2026 earnings at ($1.24) EPS. LADENBURG THALM/SH SH lowered KALA BIO from a “buy” rating to a “neutral” rating in a research report on Monday. View Our Latest Stock Analysis on KALAKALA BIO Price PerformanceShares of KALA BIO stock opened at $1.36 on Wednesday. Further ReadingReceive News & Ratings for KALA BIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KALA BIO and related companies with MarketBeat.com's FREE daily email newsletter.